

From Code Compliance to Ethics and Business Integrity

IFPMA keynote speech to International Pharmaceutical and Medical Device Compliance Congress 17th of May, 2017, Lisbon

Thomas Cueni Director General IFPMA

Email: t.cueni@ifpma.org

Twitter: @thomascueni

Our role





"A single point of contact connecting people and organizations on pharmaceutical and global health issues"

Engaging with United Nations and International Organizations



















Bridging between industry and global health community






































Our Focus Areas 2017-2018





Championing Integrity and Ethics



- Industry has made significant efforts in ensuring compliant business practices in its marketing and promotion interactions with its key stakeholders. Compared with other industries, Pharma has regulated itself beyond the existing laws.
- Evolving business models, changing regulation and legislation and shifting community expectations urge the industry to demonstrate its commitment to, and to be seen to be operating by highest ethical standards.
- The industry should be a LEADER of the ethical debate and a DRIVER of the changes in the compliance model.

From CCN to eBIC

Championing Integrity and Ethics



- A robust Code together with tools and support services to translate it into practice (capacity building, workshops, presentations at forums) will help maintain the industry's proactive role in driving ethical standards. In 2016 it was recommended for the Code to be revised and improved to better reflect the biopharmaceutical's holistic footprint. Guiding Principles and the Code are currently under review.
- Training and communication are key
- Both member Associations and Companies have a major role to play to enhance the promotion of ethical behaviors, and a dedicated working group at IFPMA is looking at this topic.

Championing Integrity and Ethics



- Without IP you don't get anywhere, but the same is true for reputation.
- Trust is basis of reputation and essential for innovation.




Crisis in Trust



2017: Trust Gap Widens

Percent trust in the four institutions of government, business, media and NGOs, 2012 to 2017



Source: 2017 Edelman Trust Barometer. The Trust Index is an average of a country's trust in the institutions of government, business, media and NGOs. Informed Public and Mass Population, 25-country global total.

Trust in the pharma sector



Pharmaceuticals Still Distrusted in Almost Half of Markets

Percent trust in the pharmaceuticals sub-sector, 2016 vs. 2017





Source: 2017 Edelman Trust Barometer. Q61F-65F. Now thinking about specific sectors within the health industry, please indicate how much you trust businesses in each of the following sectors to do what is right. Again, please use the same 9-point scale where one means that you "do not trust them at all" and nine means that you "trust them a great deal". (Top 4 Box, Trust), question asked of one-fifth of the sample. General Population, 28-country global total.


Building trust: Importance vs. Performance



Trust-Building Behaviors

Largest Gaps in Transparency and Authenticity, Leadership Representing All Stakeholders

Importance vs. performance of behavior in building trust in a health care company







Implications for Healthcare Organisations



Talk with Your Audience, Not at Them

- Create dialogue, not monologue
- Show audiences you are listening
- Use social channels to engage

Address Expectations of all Stakeholders

- Represent the interests of all audiences, not just shareholders
- Commit to actions that close gaps between expectations and performance

Demonstrate Inclusiveness

- Design content with a variety of audiences in mind, from scientists to patients to payers
- Encompass the mass population in communications

Source: 2017 Edelman Trust Barometer

Global Challenges



- Communication and Training
- Transparency / Disclosure
- Ban on Gifts (incl. branded pens, notepads)
- Items of Medical Utility (e.g. anatomic model)
- Industry involvement in Medical Education

Learn more and stay connected!

www.ifpma.org











Back up slides

The IFPMA Code is:





First established in 1981, last updated in 2012


- IFPMA Code of Practice
- Global standard for the R&D biopharmaceutical industry
- A model of self-regulation for industry's activities in medicines promotion, communication and interaction with key stakeholders such as healthcare professionals, medical institutions and patient organizations.
- Although self-regulatory, the IFPMA Code is not voluntary, it is a condition of membership to the IFPMA for both member companies and national associations.

Strong synergy between IFPMA Code and APEC Mexico City Principles









Ethics and Compliance





Promote Code of Conduct worldwide

Build trust with professional organizations

PERH INCOME STATES

Ethical pharmaceutical promotion and

communications worldwide: codes and regulations

IFPMA Code of Practice 16

Provide web-based e-learning tool and ad hoc training/seminars



HEALTH&TRUST IN THE INNOVATIVE PHARMACQUITCAL HOUSTRY

IFPMA Code of Practice



Welcome to this e-learning module about the 2012 IFPMA Code











Peer-reviewed Publications

Advocate for consistent requirements at regional and global level



Launched in January 2014













Consensus Framework for Ethical Collaboration

4 Overarching Principles

- Put patients first
- Support for Ethical Research and Innovation
- Ensure Independence and Ethical Conduct
- Promote Transparency and Accountability

*Implementation, Monitoring and Reporting
Mechanisms encouraged

19



Putting patients first

Five global healthcare organizations sign Consensus Framework for Ethical Collaboration